SAN FRANCISCO, July 31, 2018 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing innovative gene therapy
products for patients living with serious, life-threatening rare
diseases, will host a conference call and webcast to report its
second quarter 2018 financial results and provide an update on
ASPIRO, the Phase 1/2 study of AT132 in patients with X-Linked
Myotubular Myopathy. The ASPIRO update will include 24-week
clinical data and muscle biopsy results from the first three
patients treated in the study.
The conference call and webcast will be held on Tuesday, August 7, 2018 at 8:00am ET. To access the live webcast of
the conference call, please visit the Events & Presentations
page within the Investor + Media section of the Audentes website at
www.audentestx.com. Alternatively, please call 1-833-659-8620
(U.S.) or 1-409-767-9247 (international) and dial the conference ID
2572579 to access the call.
A replay of the live webcast will be available on the Audentes
website for approximately 30 days.
About AT132 for X-Linked Myotubular Myopathy
AT132 is
the Audentes product candidate being developed to treat XLMTM, a
rare monogenic disease characterized by extreme muscle weakness,
respiratory failure and early death, with an estimated 50%
mortality rate by 18 months of age. XLMTM is caused by
mutations in the MTM1 gene, which encodes the protein
myotubularin. Myotubularin plays an important role in the
development, maintenance and function of skeletal muscle
cells. AT132 is comprised of an AAV8 vector containing a
functional copy of the MTM1 gene. In May 2018, Audentes
reported positive interim data from the first dose cohort of
ASPIRO, a multicenter, ascending dose Phase 1/2 clinical
study to evaluate the safety and preliminary efficacy of AT132 in
approximately 12 XLMTM patients less than five years of age. The
preclinical development of AT132 was conducted in collaboration
with Genethon (www.genethon.fr).
AT132 has been granted PRIME and Orphan Drug designations by the
EMA, and Rare Pediatric Disease, Fast Track and Orphan Drug
designations by the FDA.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused
on developing and commercializing innovative gene therapy products
for patients living with serious, life-threatening rare
diseases. We are currently conducting
Phase 1/2 clinical studies of our lead product candidates
AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM) and
AT342 for the treatment of Crigler-Najjar Syndrome. We have
two additional product candidates in development, including AT982
for the treatment of Pompe disease, and AT307 for the treatment of
the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular
Tachycardia (CASQ2-CPVT). We are a focused, experienced and
passionate team committed to forging strong, global relationships
with the patient, research and medical communities.
For more information regarding Audentes, please
visit www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Paul Laland
415.519.6610
plaland@audentestx.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/audentes-to-release-second-quarter-2018-financial-results-and-provide-update-on-aspiro-the-phase-12-study-of-at132-in-patients-with-x-linked-myotubular-myopathy-300688571.html
SOURCE Audentes Therapeutics, Inc.